Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Collett, L, Howard, DR orcid.org/0000-0003-3333-9783, Munir, T et al. (11 more authors) (2017) Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18. 387. ISSN 1745-6215

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: CLL, FCR, Rituximab, Ibrutinib, Front-line, Phase III, Minimal residual disease (MRD), Randomised, Clinical tria
Dates:
  • Published: 22 August 2017
  • Accepted: 4 August 2017
  • Published (online): 22 August 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Funding Information:
FunderGrant number
Janssen-Cilag LtdPCI-32765CLL3003 Ibrutin
Cancer Research UKA15790
Abbvie Ltd4200822156
Depositing User: Symplectic Publications
Date Deposited: 27 Nov 2017 16:39
Last Modified: 06 Jul 2018 10:15
Status: Published
Publisher: BioMed Central
Identification Number: https://doi.org/10.1186/s13063-017-2138-6
Related URLs:

Share / Export

Statistics